Table 1.
The basic characteristics for the patients of uterine sarcoma
| histological types | |||||||
|---|---|---|---|---|---|---|---|
| Basic clinical data | Total | LG-ESS | HG-ESS | UUS | LMS | AS | |
| No. of patients(n,%) | 114 | 50(43.9) | 13(11.4) | 9(7.9) | 34(29.8) | 8(7.0) | |
| Age(years) | |||||||
| Median | 47 | 46 | 46 | 58 | 46 | 48 | |
| Range | 20-79 | 20-68 | 20-63 | 34-66 | 26-71 | 29-79 | |
| Tumor size(cm) | |||||||
| Median | 7.0 | 5.6 | 7.8 | 7.5 | 8.6 | 5.0 | |
| Range | 1.0-27.0 | 1.0-14.5 | 1.1-20.3 | 2.5-15.0 | 2.0-23.5 | 2.8-27.0 | |
| menstrual status | |||||||
| premenopausal | 80(70.2) | 38(76.0) | 9(69.2) | 2(22.2) | 26(76.5) | 5(62.5) | |
| postmenopausal | 34(29.8) | 12(24.0) | 4(30.8) | 7(77.8) | 8(23.5) | 3(37.5) | |
| US | |||||||
| Benign tumors | 56/100(56.0) | 27/44(61.4) | 5/12(41.7) | 2/9(22.2) | 19/28(67.9) | 3/7(42.9) | |
| Malignancy suspected* | 33/100(33.0) | 14/44(31.8) | 5/12(41.7) | 4/9(44.4) | 7/28(25.0) | 3/7(42.9) | |
| Malignant tumors | 11/100(11.0) | 3/44(6.8) | 2/12(16.7) | 3/9(33.3) | 2/28(7.1) | 1/7(14.3) | |
| MRI | |||||||
| Benign tumors | 16/34(47.1) | 8/15(53.3) | 1/5(20.0) | 1/3(33.3) | 6/10(60.0) | 0/1(0) | |
| Malignancy suspected | 6/34(17.6) | 3/15(20.0) | 0/5(0) | 0/3(0) | 3/10(30.0) | 0/1(0) | |
| Malignant tumors | 12/34(35.3) | 4/15(26.7) | 4/5(80.0) | 2/3(66.7) | 1/10(10.0) | 1/1(100) | |
| CT | |||||||
| Benign tumors | 5/27(18.5) | 3/8(37.5) | 0/5(0) | 0/1(0) | 2/9(22.2) | 0/4(0) | |
| Malignancy suspected | 5/27(18.5) | 3/8(37.5) | 1/5(20.0) | 0/1(0) | 1/9(11.1) | 0/4(0) | |
| Malignant tumors | 17/27(63.0) | 2/8(25.0) | 4/5(80.0) | 1/1(100) | 6/9(66.7) | 4/4(100) | |
| Tumor marker | |||||||
| CA125 abnormality | 24/70(34.3) | 11/30(36.7) | 3/10(30.0) | 1/6(16.7) | 8/19(42.1) | 1/5(20.0) | |
| LDH abnormality | 17/70(24.3) | 5/25(20.0) | 2/9(22.2) | 1/6(16.7) | 8/22(36.4) | 1/8(12.5) | |
| Preoperative pathological diagnosis | |||||||
| Fractional curettage | 18/28(64.3) | 10/14(71.4) | 2/5(40.0) | 3/3(100) | 1/3(33.3) | 2/3(66.7) | |
| Biopsy under hysteroscopy | 18/20(90.0) | 9/9(100) | 1/1(100) | 4/4(100) | 4/5(80.0) | 0/1(0) | |
| Vaginal neoplasm biopsy | 6/9(66.7) | 2/3(66.7) | 1/1(100) | 0/1(0) | 1/2(50.0) | 2/2(100) | |
| FIGO stage¶ | |||||||
| I | 82(71.9) | 35(70.0) | 8(61.5) | 7(77.8) | 27(79.4) | 5(62.5) | |
| II | 7(6.1) | 3(6.0) | 1(7.7) | 1(11.1) | 2(5.9) | 0 | |
| III | 9(7.9) | 4(8.0) | 1(7.7) | 1(11.1) | 2(5.9) | 1(12.5) | |
| IV | 15(13.2) | 7(14.0) | 3(23.1) | 0 | 3(8.8) | 2(25.0) | |
LG-ESS:low-grade endometrial stromal sarcoma; HG-ESS: high-grade endometrial stromal sarcoma; UUS: undifferentiated uterine sarcoma; LMS: leiomyosarcoma; AS: adenosarcoma; * Malignancy suspected can be understood as an ambiguous conclusion; ¶ One patient at LG-ESS group refused further therapy after diagnosed during endometrial sampling, and had no staging.